1. Safety and Efficacy of Reproductive Organ-Sparing Radical Cystectomy in Women With Variant Histology and Advanced Stage
- Author
-
Armine K. Smith, Mark Schoenberg, Andrew T. Gabrielson, Sunil H. Patel, Trinity J. Bivalacqua, Noah Hahn, Phil Pierorazio, Meredith R. Metcalf, Jean H. Hoffman-Censits, Shirley Wang, Mary Rostom, Max Kates, Natasha Gupta, and Esther Lee
- Subjects
Male ,medicine.medical_specialty ,Urology ,medicine.medical_treatment ,Ovary ,Cystectomy ,medicine ,Humans ,Genitalia ,Retrospective Studies ,Bladder cancer ,business.industry ,Advanced stage ,Muscle invasive ,Margins of Excision ,medicine.disease ,Treatment Outcome ,medicine.anatomical_structure ,Urinary Bladder Neoplasms ,Oncology ,Female ,Histopathology ,Neoplasm Recurrence, Local ,Reactive Oxygen Species ,business ,Variant histology ,Reproductive organ - Abstract
Purpose Muscle invasive bladder cancer surgical management has been historically a radical cystoprostatectomy in males and an anterior exenteration in females. Uterine, ovarian, and vaginal preservation are utilized, but raise concerns regarding risk to oncologic control, especially in variant histopathology or advanced stage. Materials and Methods A retrospective single institutional analysis identified radical cystectomies performed in women, including those with variant histology, which were defined as reproductive organ sparing (uterine, vaginal, and ovary sparing) or non-organ sparing. The Kaplan-Meier method was used for recurrence-free (RFS) cancer specific survival (CSS) and overall (OS) survival in patients with advanced disease. Results From 2000 to 2020, 289 women were identified, 188 underwent reproductive organ-sparing cystectomy. No statistical differences were noted for clinical parameters or presence of variant histology for organ-sparing (ROS) and non-organ sparing (non-ROS). Positive margin rates did not differ for ROS and non-ROS; 4.3% vs 7.9%, p=0.19, respectively. Median RFS was not statistically significantly different for ROS vs non-ROS (26.1 vs 15.3 months) p=0.937 HR 1.024. CSS was not statistically different for ROS vs non-ROS (36.3 vs 28.6 months), p=0.755 HR 0.9. OS was not statistically different for ROS vs non-ROS (25.8 v 23.8 months), p=0.5 HR=1.178. Variant histology did not change survival (HR 1.1, p=0.643). Conclusions In this analysis, ROS in women with advanced disease did not increase positive margin rates or decrease RFS, CSS, or OS compared to non-ROS. Variant histology did not decrease survival odds. Based on preoperative assessment and intraoperative findings, ROS in patients with variant histology and advanced disease should be considered.
- Published
- 2022
- Full Text
- View/download PDF